Find a Clinical Trial

Trial Description: This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: - mirvetuximab soravtansine (IMGN853) - pembrolizumab

• Conditions: endometrial cancer
• Phase: II
• Trial ID: NCT03835819
• Protocol ID: 18-602

Trial Description: This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.

• Conditions: metastatic endometrial cancer
• Phase: II
• Trial ID: NCT02912572
• Protocol ID: 16-322

Trial Description: The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

• Conditions: endometrial cancer, endometrial cancer stage, ovarian cancer, ovarian cancer stage 3, ovarian cancer stage iii, ovarian cancer stage iv, ovarian carcinoma
• Phase: Feasibility / Pilot
• Trial ID: NCT04997096
• Protocol ID: 21-299

Trial Description: This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

• Conditions: endometrial cancer
• Phase: I/II
• Trial ID: NCT04486352
• Protocol ID: 21-702

Trial Description: This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs involved in this study are: - Abemaciclib (also known as Verzenio™) - Letrozole (also known as Femara®)

• Conditions: endometrial cancer
• Phase: II
• Trial ID: NCT03675893
• Protocol ID: 18-301

Trial Description: This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial cancer that has come back (recurrent) or spread to other places in the body (advanced or metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.

• Conditions: advanced endometrial carcinoma, metastatic endometrial carcinoma, recurrent endometrial carcinoma, stage iii uterine corpus cancer ajcc v7, stage iv uterine corpus cancer ajcc v7
• Phase: II
• Trial ID: NCT03367741
• Protocol ID: 18-715

Trial Description: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

• Conditions: carcinosarcoma, endometrial cancer, ovarian cancer, uterine cancer
• Phase: II
• Trial ID: NCT03395080
• Protocol ID: 17-499

Trial Description: The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

• Conditions: advanced breast cancer, breast cancer, endometrial cancer, metastatic breast cancer
• Phase: I
• Trial ID: NCT04188548
• Protocol ID: 20-118

Trial Description: To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo concurrent weight loss surgery and hysterectomy within 8 weeks of first appointment with a gynecologic oncologist (or 12 weeks for EIN patients).

• Conditions: ein, endometrial cancer stage i, endometrial carcinoma, endometrial intraepithelial neoplasia, obesity
• Phase: Not Applicable
• Trial ID: NCT04839614
• Protocol ID: 19-419

Trial Description: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

• Conditions: bladder cancer biliary tract cancer cervical cancer endometrial cancer ovarian cancer pancreatic cancer rare tumors
• Phase: II
• Trial ID: NCT04482309
• Protocol ID: 21-051

Trial Description: This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: - Durvalumab - Tremelimumab

• Conditions: metastatic cervical cancer, metastatic endometrial cancer, metastatic ovarian cancer, metastatic vaginal cancer, metastatic vulvar cancer, recurrent cervical carcinoma, recurrent endometrial cancer, recurrent gynecological cancer, recurrent ovarian carcinoma, recurrent vaginal cancer, recurrent vulvar cancer
• Phase: I
• Trial ID: NCT03277482
• Protocol ID: 17-382

Trial Description: A Study of XMT-1660 in Solid Tumors

• Conditions: breast cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT05377996
• Protocol ID: 22-547

Trial Description: The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

• Conditions: cervical cancer, endometrial cancer, melanoma, non small cell lung cancer (nsclc), ovarian cancer, sarcoma, solid tumors, thyroid cancer
• Phase: I/II
• Trial ID: NCT02988817
• Protocol ID: 18-183

Trial Description: This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or endometrial cancer. Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of deoxyribonucleic acid (DNA) damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component

• Conditions: endometrial serous adenocarcinoma, metastatic malignant solid neoplasm, unresectable malignant solid neoplasm
• Phase: I
• Trial ID: NCT04585958
• Protocol ID: 21-151

Trial Description: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D

• Conditions: advanced cancer, angiosarcoma, colorectal cancer without liver metastases, endometrial cancer, fibrolamellar carcinoma, melanoma, non-small-cell lung cancer, ovarian cancer
• Phase: I
• Trial ID: NCT03860272
• Protocol ID: 19-132

Trial Description: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2

• Conditions: advanced solid tumor, carcinosarcoma, ccne1 amplification, endometrial cancer, er+ breast cancer, esophageal adenocarcinoma, gastric cancer, her2-negative breast cancer, ovarian cancer
• Phase: I/II
• Trial ID: NCT05252416
• Protocol ID: 22-142

participant cohort (Cohort 1: small cell lung cancer [SCLC]; Cohort 2: squamous cell carcinoma of the head and neck [SCCHN]; Cohort 3: gastrointestinal (GI) cancers with known microsatellite instability-high/mismatch repair deficiency (MSI-H/MMRd) or other deoxyribonucleic acid (DNA) damage repair (DDR) abnormalities, including homologous recombination deficiency (HRD); Cohort 4: platinum-resistant epithelial ovarian cancer [EOC], endometrial cancer, primary peritoneal cancer (PPC) or cervical cancer, with known MSIH/MMRd, hereditary/somatic mutations of the breast cancer 1 (BRCA1) and BRCA2 genes or other DNA DDR abnormalities (incl. HRD).

• Conditions: solid tumor
• Phase: I/II
• Trial ID: NCT04122625
• Protocol ID: 19-760

Trial Description: This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal

• Conditions: castration-resistant prostate cancer, colorectal cancer, differentiated thyroid cancer, endometrial cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, hepatocellular carcinoma, lower esophageal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma
• Phase: I
• Trial ID: NCT03170960
• Protocol ID: 17-492

Trial Description: The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors

• Conditions: breast cancer, colon cancer, colorectal cancer, endometrial cancer, neoplasms, ovarian cancer, pancreas cancer, pancreatic cancer, rectal cancer, soft tissue sarcoma, solid tumors, triple negative breast cancer
• Phase: I
• Trial ID: NCT02632448
• Protocol ID: 18-524

Trial Description: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent

• Conditions: adrenocortical carcinoma, advanced solid tumours, breast cancer, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma (hnscc), her2-negative breast cancer, ovarian cancer, triple negative breast cancer (tnbc), uveal melanoma
• Phase: I
• Trial ID: NCT03746431
• Protocol ID: 19-824

Trial Description: This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

• Conditions: bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, metastatic castration resistant prostate cancer, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell cancer, sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer
• Phase: I
• Trial ID: NCT03454451
• Protocol ID: 18-335

Trial Description: In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475

• Conditions: advanced cancer, advanced solid tumors, anal cancer, anal carcinoma, bile duct cancer, biliary cancer, carcinoid tumor, cervical cancer, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, endometrial cancer, endometrial carcinoma, mesothelioma, neuroendocrine tumor, parotid gland cancer, salivary cancer, salivary gland cancer, salivary gland carcinoma, small cell lung cancer (sclc), small cell lung carcinoma, thyroid cancer, thyroid carcinoma, vulvar cancer, vulvar carcinoma
• Phase: II
• Trial ID: NCT02628067
• Protocol ID: 16-030

Trial Description: This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

• Conditions: appendiceal adenocarcinoma, carcinoma non-small cell lung, colorectal neoplasms, endometrial neoplasms, esophageal neoplasms, exocrine pancreatic adenocarcinoma, gastroesophageal junction carcinoma, her2 negative breast neoplasms, ovarian neoplasms, pseudomyxoma peritonei, stomach neoplasms, uterine cervical neoplasms
• Phase: I
• Trial ID: NCT04665921
• Protocol ID: 21-001

Trial Description: The purpose of this study is to determine the efficacy of a group-based and web-delivered psychosocial intervention for ovarian cancer survivors (Mindful Living [ML]) compared to a health promotion condition (Healthy Lifestyles [HL]) in increasing health related quality of life (HRQOL) and decreasing perceived stress, depressive mood (primary aims), anxiety, and fatigue (secondary aims) across a 12-month period.

• Conditions: ovarian cancer
• Phase: Not Applicable
• Trial ID: NCT04533763
• Protocol ID: 21-745

Trial Description: The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors

• Conditions: endometrial carcinoma, melanoma, pancreatic carcinoma, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT02807844
• Protocol ID: 16-491

Trial Description: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.

• Conditions: breast cancer
• Phase: I
• Trial ID: NCT05307705
• Protocol ID: 22-168

Trial Description: This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.

• Conditions: appendix cancer, colorectal cancer
• Phase: II
• Trial ID: NCT01815359
• Protocol ID: 17-177

Trial Description: First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2

• Conditions: advanced solid tumor, diffuse large b cell lymphoma, lymphoma t-cell, mesothelioma malignant, prostatic neoplasms castration-resistant
• Phase: I/II
• Trial ID: NCT04104776
• Protocol ID: 19-670

Trial Description: This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD

• Conditions: neoplasms
• Phase: I
• Trial ID: NCT02715284
• Protocol ID: 16-393

Trial Description: This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.

• Conditions: head & neck cancer, lung cancer squamous cell, pancreatic cancer, solid tumors
• Phase: I
• Trial ID: NCT03065062
• Protocol ID: 16-499

Trial Description: This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors

• Conditions: locally advanced or metastatic solid tumor
• Phase: I/II
• Trial ID: NCT03601897
• Protocol ID: 19-367

Trial Description: This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

• Conditions: solid tumor
• Phase: I
• Trial ID: NCT03364400
• Protocol ID: 18-609

Trial Description: This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: - Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a - Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately

• Conditions: hormone receptor positive breast cancer, non-small cell lung cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03401385
• Protocol ID: 18-061

Trial Description: This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: - Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of DS-7300a. - Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of DS-7300a when administered as a single agent. This study is expected to last approximately 5

• Conditions: advanced solid tumor, malignant solid tumor
• Phase: I/II
• Trial ID: NCT04145622
• Protocol ID: 20-725

Trial Description: This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

• Conditions: estrogen receptor (er)-positive her2-negative locally advanced or metastatic breast cancer
• Phase: III
• Trial ID: NCT05306340
• Protocol ID: 22-265

Trial Description: Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration

• Conditions: ovarian neoplasms, ovarian fallopian tube and primary peritoneal carcinoma
• Phase: III
• Trial ID: NCT03602859
• Protocol ID: 18-486

Trial Description: This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow

• Conditions: colorectal carcinoma, endometrial carcinoma, melanoma, neuroblastoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, recurrent desmoid fibromatosis, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent hepatocellular carcinoma, recurrent malignant solid neoplasm, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, refractory desmoid fibromatosis, refractory ewing sarcoma, refractory hepatoblastoma, refractory hepatocellular carcinoma, refractory malignant solid neoplasm, refractory non-hodgkin lymphoma, refractory osteosarcoma, solid pseudopapillary neoplasm of the pancreas, wilms tumor
• Phase: I/II
• Trial ID: NCT04851119
• Protocol ID: 21-664

Trial Description: The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given to cancer patients. Further, the response of the cancer to the treatment will be determined.

• Conditions: advanced solid tumor, mantle cell lymphoma, non-hodgkin's lymphoma
• Phase: I
• Trial ID: NCT03188965
• Protocol ID: 18-441

Trial Description: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy

• Conditions: advanced solid tumors with her2 mutation eg:colorectal urothelial gastric hepatobiliary endometrial melanoma ovarian cervical salivary gland pancreatic breast
• Phase: II
• Trial ID: NCT04639219
• Protocol ID: 20-650

Trial Description: This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors

• Conditions: solid tumor
• Phase: I/II
• Trial ID: NCT03834948
• Protocol ID: 19-163

Trial Description: This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. The study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). Alternative dosing schedules will be explored in Part 1B and the recommended Part 2 dose and schedule will be further evaluated in Part 2. Subjects will participate in a screening period of up to 14 days. Dosing

• Conditions: solid tumor adult
• Phase: I
• Trial ID: NCT03355066
• Protocol ID: 19-567

Trial Description: This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

• Conditions: fallopian tube cancer, ovarian cancer, peritoneal cancer
• Phase: II
• Trial ID: NCT02873962
• Protocol ID: 16-263

Trial Description: The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking the study drug causes any significant or undesirable side effects in women with DCIS. The researchers hope that this study will help them determine if taking the study drug is safe in women taking DCIS and if it can possibly reduce the risk of developing breast cancer in women with DCIS.

• Conditions: ductal breast carcinoma in situ, postmenopausal
• Phase: II
• Trial ID: NCT02694809
• Protocol ID: 18-075

Trial Description: The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.

• Conditions: gynecologic cancer
• Phase: II
• Trial ID: NCT03277469
• Protocol ID: 17-128

Trial Description: Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.

• Conditions: high grade serous carcinoma
• Phase: I/II
• Trial ID: NCT03462342
• Protocol ID: 20-320

Trial Description: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.

• Conditions: ovarian neoplasms
• Phase: I/II
• Trial ID: NCT03574779
• Protocol ID: 18-303

Trial Description: This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.

• Conditions: fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, figo grade 1 endometrial endometrioid adenocarcinoma, figo grade 2 endometrial endometrioid adenocarcinoma, high grade endometrial endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian seromucinous carcinoma, ovarian undifferentiated carcinoma, platinum-sensitive ovarian carcinoma, primary peritoneal carcinosarcoma, primary peritoneal high grade serous adenocarcinoma, primary peritoneal transitional cell carcinoma, primary peritoneal undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent low grade fallopian tube serous adenocarcinoma, recurrent ovarian carcinoma, recurrent ovarian carcinosarcoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian low grade serous adenocarcinoma, recurrent ovarian mucinous adenocarcinoma, recurrent ovarian transitional cell carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal low grade serous adenocarcinoma
• Phase: I
• Trial ID: NCT04092270
• Protocol ID: 20-271

Trial Description: This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth

• Conditions: fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma
• Phase: II/III
• Trial ID: NCT02502266
• Protocol ID: 16-715

Trial Description: This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumors compared with conventional MRI

• Conditions: gynecologic tumor
• Phase: Not Applicable
• Trial ID: NCT03993210
• Protocol ID: 19-056

Trial Description: This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors

• Conditions: solid tumors
• Phase: I
• Trial ID: NCT02660034
• Protocol ID: 18-009